Edgewise Therapeutics Inc (EWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has a cash flow conversion efficiency ratio of -0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.78 Million) by net assets ($558.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Edgewise Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Edgewise Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EWTX liabilities breakdown for a breakdown of total debt and financial obligations.
Edgewise Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edgewise Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
-0.140x |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
|
Towne Bank
NASDAQ:TOWN
|
0.048x |
|
Navan, Inc. Class A Common Stock
NASDAQ:NAVN
|
0.029x |
|
TORM plc
CO:TRMD-A
|
0.056x |
|
Nien Made Enterprise Co Ltd
TW:8464
|
0.048x |
|
Fujian Kuncai Material Tech
SHG:603826
|
0.061x |
|
EXOSENS PROM
PA:EXENS
|
0.135x |
Annual Cash Flow Conversion Efficiency for Edgewise Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see EWTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $459.22 Million | $-109.03 Million | -0.237x | +17.67% |
| 2023-12-31 | $318.83 Million | $-91.95 Million | -0.288x | -89.97% |
| 2022-12-31 | $346.72 Million | $-52.63 Million | -0.152x | -24.31% |
| 2021-12-31 | $274.38 Million | $-33.51 Million | -0.122x | -127.89% |
| 2020-12-31 | $-33.42 Million | $-14.63 Million | 0.438x | -19.53% |
| 2019-12-31 | $-16.85 Million | $-9.17 Million | 0.544x | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company d… Read more